company background image
NUVL logo

Nuvalent NasdaqGS:NUVL Stock Report

Last Price

US$77.78

Market Cap

US$5.1b

7D

-1.8%

1Y

79.8%

Updated

14 Jun, 2024

Data

Company Financials +

Nuvalent, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nuvalent
Historical stock prices
Current Share PriceUS$77.78
52 Week HighUS$89.39
52 Week LowUS$38.78
Beta1.27
1 Month Change8.51%
3 Month Change-3.74%
1 Year Change79.80%
3 Year Changen/a
5 Year Changen/a
Change since IPO314.83%

Recent News & Updates

Nuvalent: NVL-655 Could Bring Blockbuster Potential

Jun 14

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Apr 22
Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Recent updates

Nuvalent: NVL-655 Could Bring Blockbuster Potential

Jun 14

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Apr 22
Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024

Feb 26

Is Nuvalent, Inc. (NASDAQ:NUVL) Trading At A 36% Discount?

Jan 07
Is Nuvalent, Inc. (NASDAQ:NUVL) Trading At A 36% Discount?

Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth

Sep 23
Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Jun 10
Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

We're Interested To See How Nuvalent (NASDAQ:NUVL) Uses Its Cash Hoard To Grow

Feb 24
We're Interested To See How Nuvalent (NASDAQ:NUVL) Uses Its Cash Hoard To Grow

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Sep 13
Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Nuvalent GAAP EPS of -$0.38 beats by $0.03

Aug 10

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

May 28
Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely

Oct 29
We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely

Shareholder Returns

NUVLUS BiotechsUS Market
7D-1.8%0.02%1.2%
1Y79.8%6.7%20.6%

Return vs Industry: NUVL exceeded the US Biotechs industry which returned 7.4% over the past year.

Return vs Market: NUVL exceeded the US Market which returned 20.5% over the past year.

Price Volatility

Is NUVL's price volatile compared to industry and market?
NUVL volatility
NUVL Average Weekly Movement6.2%
Biotechs Industry Average Movement10.4%
Market Average Movement5.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.9%

Stable Share Price: NUVL has not had significant price volatility in the past 3 months.

Volatility Over Time: NUVL's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017106Jim Porterwww.nuvalent.com

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Nuvalent, Inc. Fundamentals Summary

How do Nuvalent's earnings and revenue compare to its market cap?
NUVL fundamental statistics
Market capUS$5.10b
Earnings (TTM)-US$145.51m
Revenue (TTM)n/a

0.0x

P/S Ratio

-34.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NUVL income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$145.51m
Earnings-US$145.51m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.25
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did NUVL perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.